Alberto Ortíz

Research interests

Publications

• Chronic kidney disease and the global public health agenda: an international consensus

  Nature Reviews Nephrology · 2024 · https://doi.org/10.1038/s41581-024-00820-6

• Targeting the progression of chronic kidney disease

  Nature Reviews Nephrology · 2020 · https://doi.org/10.1038/s41581-019-0248-y

• An update review of intradialytic hypotension: concept, risk factors, clinical implications and management

  Clinical Kidney Journal · 2020 · https://doi.org/10.1093/ckj/sfaa078

• SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA

  Nephrology Dialysis Transplantation · 2019 · https://doi.org/10.1093/ndt/gfy407

• La carga de enfermedad en España: resultados del Estudio de la Carga Global de las Enfermedades 2016

  Medicina Clínica · 2018 · https://doi.org/10.1016/j.medcli.2018.05.011

• Fabry disease revisited: Management and treatment recommendations for adult patients

  Molecular Genetics and Metabolism · 2018 · 10.1016/j.ymgme.2018.02.014

• Lipid management in patients with chronic kidney disease

  Nature Reviews Nephrology · 2018 · https://doi.org/10.1038/s41581-018-0072-9

• La carga de enfermedad en España: resultados del Estudio de la Carga Global de las Enfermedades 2016

  Medicina Clínica · 2018 · https://doi.org/10.1016/j.medcli.2018.05.011

• European expert consensus statement on therapeutic goals in Fabry disease

  Molecular Genetics and Metabolism · 2018 · https://doi.org/10.1016/j.ymgme.2018.06.004

• Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)*

  Nephrology Dialysis Transplantation · 2017 · https://doi.org/10.1093/ndt/gfw433

• The systemic nature of CKD

  Nature Reviews Nephrology · 2017 · https://doi.org/10.1038/nrneph.2017.52

• Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

  Kidney International · 2016 · https://doi.org/10.1016/j.kint.2016.10.004

• Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry

  Journal of Medical Genetics · 2016 · https://doi.org/10.1136/jmedgenet-2015-103486

• The double challenge of resistant hypertension and chronic kidney disease

  The Lancet · 2015 · https://doi.org/10.1016/s0140-6736(15)00418-3

• Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides

  Journal of the American Society of Nephrology · 2015 · https://doi.org/10.1681/asn.2014050423

• Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure

  The Lancet · 2014 · https://doi.org/10.1016/s0140-6736(14)60384-6

• Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation

  Nephrology Dialysis Transplantation · 2011 · https://doi.org/10.1093/ndt/gfr420

• Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry

  Molecular Genetics and Metabolism · 2007 · https://doi.org/10.1016/j.ymgme.2007.09.013

Current projects

No projects listed.